logo conference-reports

Cobertura de Eventos

Patrocínio educacional da logo MSD Oncology

ASCO-GI 2020 – Unresectable HCC: atezolizumab plus bevacizumab tops sorafenib in patient-reported outcomes

Quality of life analysis of the IMbrave150 trial.